Lorundrostat: New Hope for Hypertension in CKD Patients
Mineralys Therapeutics’ lorundrostat shows compelling results for patients grappling with hypertension and chronic kidney disease (CKD).The Explore-CKD trial revealed that this novel drug significantly reduced systolic blood pressure. Additionally, it lowered proteinuria, offering the possibility of renal protection. Hypertension is a serious concern for CKD patients; therefore, the potential of lorundrostat to manage this condition is notably promising. The trial results also suggest a favorable safety profile, further bolstering its appeal. News Directory 3 keeps you informed about the latest developments in healthcare. Lorundrostat could offer a dual-action treatment strategy. Will larger studies cement its role in treating hypertension? Discover what’s next …
Lorundrostat Shows Promise for Hypertension and Kidney Disease
Updated June 22, 2025
lorundrostat, developed by Mineralys Therapeutics, has demonstrated positive results in a phase 2 trial. The Explore-CKD trial revealed that the drug significantly lowered systolic blood pressure and proteinuria in patients with both hypertension and chronic kidney disease (CKD). These findings suggest lorundrostat’s potential as a dual-action treatment, offering both cardiovascular and renal protection.
The Explore-CKD trial included 59 participants with hypertension and CKD, characterized by specific eGFR and albuminuria levels. The study employed a double-blind, placebo-controlled design, evaluating a 25 mg daily dose of lorundrostat alongside standard therapies like SGLT2 inhibitors and ACE inhibitors or angiotensin receptor blockers.
Matthew Weir, director of the Division of Nephrology at the University of Maryland Medical Center, noted the dangers of prolonged high blood pressure in patients with impaired kidney function. He said such elevations can damage kidney blood vessels, further hindering their function.
The trial met its primary endpoint, showing a 7.5 mmHg placebo-adjusted reduction in systolic automated office blood pressure (P =.0024). researchers considered this reduction clinically meaningful, especially in patients with renal compromise. Furthermore, lorundrostat reduced urine albumin-to-creatinine ratio (UACR) by 25.6% compared to the placebo (P = .0015), suggesting potential kidney protective benefits. A slight decline in eGFR was observed, consistent with the effects of similar agents and considered part of the therapeutic mechanism.
While adverse events were limited, 2 patients discontinued lorundrostat due to kidney function changes, and 3 experienced confirmed hyperkalemia, none exceeding safety thresholds. Two serious adverse events occurred during the lorundrostat phase, but none during the placebo phase.
“The evidence generated from this trial demonstrates the unique mechanism of action and benefit of lorundrostat in lowering systolic blood pressure and UACR,” Weir said. ”Lorundrostat shows significant potential in the management of hypertension and related kidney disease.”
What’s next
Mineralys Therapeutics is continuing research on lorundrostat with ongoing studies, including the Transform-HTN extension trial and the Explore-OSA trial, which focuses on patients with obstructive sleep apnea and uncontrolled hypertension. These efforts aim to solidify lorundrostat’s position as a treatment for aldosterone-driven conditions.